The footprints of cancer development: Cancer biomarkers

Cancer Treatment Reviews

Volumn 35, Issue 3, 2009, Pages 193-200

  Ullah, Mohd Fahad ^a   Aatif, Mohammad ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Biomarkers; Cancer; Diagnosis; Microarray profile; Proteomics

Indexed keywords

AUTOANTIBODY; CATHEPSIN; CYSTEINE PROTEINASE; KALLIKREIN; MICRORNA; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; TUMOR MARKER; UROKINASE;

BREAST CANCER; CANCER DIAGNOSIS; CANCER INVASION; CANCER RISK; DIAGNOSTIC VALUE; DNA METHYLATION; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HUMAN; METASTASIS; NANOTECHNOLOGY; PROGNOSIS; PROSTATE CANCER; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; NANOTECHNOLOGY; NEOPLASM PROTEINS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDE HYDROLASES; PROTEOMICS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 64049096712     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.10.004     Document Type: Review

References (146)

1. American Cancer Society. Cancer statistics; 2005. www.cancer.org.
2. Jemal A., Murray T., Ward E., et al. Cancer statistics. CA Cancer J Clin 55 1 (2005) 10-30
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J Clin 57 1 (2007) 43-66
4. Etzioni R., Urban N., Ramsey S., et al. The case for early detection. Nat Rev Cancer 3 4 (2003) 243-252
5. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5 (2006) 785-799
6. Mohamed M.M., and Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6 9 (2006) 764-775
7. Palermo C., and Johanna A.J. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 29 1 (2008) 22-28
8. Rawlings ND, Barrett AJ. MEROPS - the peptidase database. Release 6.30. http://merops.sanger.ac.uk/2003.
9. Barrett A.J., and Rawlings N.D. Evolutionary lines of cysteine peptidases. Biol Chem 382 5 (2001) 727-733
10. Berdowska I. Cysteine proteases as disease markers. Clin Chim Acta 342 1-2 (2004) 41-69
11. Bromme D., and Kaleta J. Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. Curr Pharm Des 8 18 (2002) 1639-1658
12. Turk D., and Guncar G. Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr D Biol Crystallogr 59 (2003) 203-213
13. Gocheva V., and Johanna A.J. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6 1 (2007) 60-64
14. Joyce J.A., Baruch A., and Chehade K. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5 5 (2004) 443-453
15. Rao J.S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3 7 (2003) 489-501
16. Grimm J., Kirsch D.G., and Antiago P.M. Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc Natl Acad Sci USA 102 40 (2005) 14404-14409
17. Jedeszko C., and Sloane B.F. Cysteine cathepsins in human cancer. Biol Chem 385 11 (2004) 1017-1027
18. Joyce J.A., and Hanahan D. Multiple roles for cysteine cathepsins in cancer. Cell Cycle 315 12 (2004) 1516-1519
19. Kos J., Werle B., Lah T., and Brunner N. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J Biol Markers 15 1 (2000) 84-89
20. Lah T.T., and Kos J. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol Chem 379 2 (1998) 125-130
21. Koblinski J.E., Ahram M., and Sloane B.F. Unraveling the role of proteases in cancer. Clin Chim Acta 291 2 (2000) 113-135
22. Pelosi G., Pasini F., Bresaola E., et al. High-affinity monomeric 67-kD laminin receptors and prognosis in pancreatic endocrine tumours. J Pathol 183 1 (1997) 62-69
23. Levicar N., Kos J., Blejec A., et al. Comparison of Potential biological markers Cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathalogical data of breast carcinoma patients. Cancer Detection Prev 26 1 (2002) 42-49
24. Borgono C.A., Michael I.P., and Diamandis E.P. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2 5 (2004) 257-280
25. Paliouras M., Borgono C., and Diamandis E.P. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 249 1 (2007) 61-79
26. Obiezu C.V., Scorilas A., Katsaros D., et al. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 7 8 (2001) 2380-2386
27. Kim H., Scorilas A., Katsaros D., et al. Human kallikrein gene 5 (KLK5) expressions is an indicator of poor prognosis in ovarian cancer. Br J Cancer 84 5 (2001) 643-650
28. Liu X.L., Wazer D.E., Watanabe K., and Band V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 56 14 (1996) 3371-3379
29. Yousef G.M., Chang A., and Diamandis E.P. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem 275 16 (2000) 11891-11898
30. Yousef G.M., Magklara A., and Diamandis E.P. KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 69 3 (2000) 331-341
31. Bhattacharjee A., Richards W.G., Staunton J., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98 24 (2001) 13790-13795
32. Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63 24 (2003) 8614-8622
33. Roman-Gomez J., Jimenez-Velasco A., Agirre X., et al. The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia 18 2 (2004) 362-365
34. Scorilas A., and Gregorakis A.K. MRNA expression analysis of human kallikrein 11 (KLK11) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy. Biol Chem 387 6 (2006) 789-793
35. Yousef G.M., Stephan C., Scorilas A., et al. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 56 4 (2003) 287-292
36. Jema A., Tiwari R.C., Murray T., Ghafoor A., et al. Cancer statistics. CA Cancer J Clin 54 1 (2004) 8-29
37. Luo L.Y., Rajpert-De Meyts E.R., Jung K., and Diamandis E.P. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer 85 2 (2001) 220-224
38. Yousef G.M., Magklara A., Chang A., Jung K., Katsaros D., and Diamandis E.P. Cloning of a new member of the human kallikrein gene family, KLK14, which is downregulated in different malignancies. Cancer Res 61 8 (2001) 3425-3431
39. Chang A., Yousef G.M., Jung K., Rajpert-De Meyts E., and Diamandis E.P. Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: differential expression in the human testis and testicular cancer. Anticancer Res 21 5 (2001) 3147-3152
40. Dass K., Ahmad A., Azmi A.S., Sarkar S.H., and Sarkar F.H. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34 2 (2008) 122-136
41. Fisher J.L., Mackie P.S., Howard M.L., Zhou H., and Choong P.F. The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin Cancer Res 7 6 (2001) 1654-1660
42. Swiercz R., Wolfe J.D., Zaher A., and Jankun J. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin Cancer Res 4 4 (1998) 869-877
43. Shiomi H., Eguchi Y., Tani T., Kodama M., and Hattori T. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 156 2 (2000) 567-575
44. Ji F., Chen Y.L., Jin E.Y., Wang W.L., Yang Z.L., and Li Y.M. Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer. World J Gastroenterol 11 21 (2005) 3222-3226
45. Shetty S., Kumar A., Johnson A., Pueblitz S., and Idell S. Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis. Am J Physiol 268 6 pt 1 (1995) L972-L982
46. Memarzadeh S., Kozak K.R., Chang L., et al. Urokinase plasminogen activator receptor: prognostic biomarker for endometrial cancer. Proc Natl Acad Sci USA 99 16 (2002) 10647-10652
47. Chambers S.K., Gertz Jr. R.E., Ivins C.M., and Kacinski B.M. The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 75 7 (1995) 1627-1633
48. Figler B.D., Reuther A.M., Dhar N., et al. Preoperative PSA is still predictive of cancer volume and grade in late PSA era. Urology 70 4 (2007) 711-716
49. Lilja H., Ulmert D., Björk T., et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44-50 years. J Clin Oncol 25 4 (2007) 431-436
50. Fang J., Metter E.J., Landis P., Chan D.W., Morrell C.H., and Carter H.B. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the baltimore longitudinal study of aging. Urology 58 3 (2001) 411-416
51. Loeb S., Roehl K.A., Antenor J.A., Catalona W.J., Suarez B.K., and Nadler R.B. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 Years old. Urology 67 2 (2006) 316-320
52. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 22 (2004) 2239-2246
53. Vickers A.J., Ulmert D., Serio A.M., et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer 121 10 (2007) 2212-2217
54. Brawer M.K., Cheli C.D., Neaman I.E., et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 163 5 (2000) 1476-1480
55. Catalona W.J., Smith D.S., and Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277 18 (1997) 1452-1455
56. Catalona W.J., Partin A.W., Finlay J.A., et al. Use of percentage of free prostate specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 54 2 (1999) 220-224
57. Partin A.W., Catalona W.J., and Smith D.S. Use of human glandular kallikrein 2 for detection of prostate cancer: preliminary analysis. Urology 54 5 (1999) 839-845
58. Babaian R.J., Fritsche H., Ayala A., et al. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/ml. Urology 56 6 (2000) 1000-1006
59. Stangelberger A., Margreiter M., Seitz C., and Djavan B. Prostate cancer screening markers. JMHG 4 3 (2007) 233-244
60. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 19 (1998) 1542-1547
61. Djavan B., Zlotta A., Kratzik C., et al. PSA, PSA density, PSA density of transitional zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 25 to 40 ng/ml. Urology 54 3 (1999) 517-522
62. Porter J.R., Hayward R., and Brawer M.K. The significance of short term PSA change in men undergoing ultrasound guided prostate biopsy. J Urol 264 (1994) 239A
63. Horninger W., Cheli C.D., Babaian R.J., et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate- specific antigen levels of 2 to 4 nanograms per milliliter. Urology 60 4 (2002) 31-35
64. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. A precursor form of prostate specific antigen is highly elevated in prostate cancer compared with benign transitional zone prostate tissue. Cancer Res 60 3 (2000) 756-759
65. Mikolajczyk S.D., Grauer L.S., Millar L.S., et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50 5 (1997) 710-714
66. Mikolajczyk S.D., Marker K.M., Millar L.S., et al. A truncated precursor form of prostate specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61 18 (2001) 6958-6963
67. Peter J., Unverzagt C., Krogh T.N., Vorm O., and Hoesel W. Identification of precursor forms of free prostate specific antigen in serum of prostate cancer patients by immunosorption and spectrometry. Cancer Res 61 3 (2001) 957-962
68. Mikolaiczyk S.D., and Rittenhouse H.G. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 52 2 (2003) 86-91
69. Sokoll L.J., Chan D.W., and Mikolajczyk S.D. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis. Urology 59 (2002) 261-265
70. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2.4-4 ng/ml. J Urol 170 6 (2003) 2181-2185
71. Bussemakers M.J., Van Bokhoven A., Verhaegh G.W., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 23 (1999) 5975-5979
72. Mintz P.J., Kim J., Do K.A., et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 21 1 (2003) 57-63
73. Montenarh M. Humoral immune response against the growth suppressor p53 in human malignancies. In: Shoenfeld Y., and Gershwin M.E. (Eds). Cancer and autoimmunity (2000), Elsevier, Amsterdam, NY 193-203
74. Korneeva I., Bongiovanni A.M., Girotra M., Caputo T.A., and Witkin S.S. Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers. Am J Obstet Gynecol 183 1 (2000) 18-21
75. Kirman I., Kalantarov G.F., Lobel L.I., et al. Isolation of native human monoclonal autoantibodies to breast cancer. Hybrid Hybridomics 21 6 (2002) 405-414
76. Dorn C., Knobloch C., Kupka M., Morakkabati-Spitz N., and Schmolling J. Paraneoplastic neurological syndrome: patient with anti-Yo antibody and breast cancer: a case report. Arch Gynecol Obstet 269 1 (2003) 62-65
77. Pittock S.J., Lucchinetti C.F., and Lennon V.A. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 53 5 (2003) 580-587
78. Trivers G.E., De Benedetti V.M., Cawley H.L., et al. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 2 10 (1996) 1767-1775
79. Frenkel K., Karkoszka J., Glassman T., et al. Serum autoantibodies recognizing 5- hydroxymethyl-20-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women. Cancer Epidemiol Biomarkers Prev 7 1 (1998) 49-57
80. Tomkiel J.E., Alansari H., Tang N., et al. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. Clin Cancer Res 8 3 (2002) 752-758
81. Zhong L., Coe S.P., Stromberg A.J., Khattar N.H., Jett J.R., and Hirschowitz E.A. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 1 6 (2006) 513-519
82. Wang X., Yu J., Sreekumar A., et al. Autoantibody signatures in prostate cancer. N Engl J Med 353 12 (2005) 1224-1235
83. Luo J., Zha S., Gage W.R., et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62 8 (2002) 2220-2226
84. Rubin M.A., Zhou M., Dhanasekaran S.M., et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287 13 (2002) 1662-1670
85. Sreekumar A., Laxman B., Rhodes D.R., et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 96 11 (2004) 834-843
86. Krebs E.G., and Beavo J.A. Phosphorylation-dephosphorylation of enzymes. Annu Rev Biochem 48 (1979) 923-939
87. Cho Y.S., Park Y.G., Lee Y.N., et al. Extracellular protein kinase A as a cancer biomarker: its expression by tumor cells and reversal by a myristate-lacking Ca and RIIh subunit overexpression. Proc Natl Acad Sci USA 97 2 (2000) 835-840
88. Cvijic M.E., Kita T., Shih W., DiPaola R.S., and Chin K.V. Extracellular catalytic subunit activity of the cAMPdependent protein kinase in prostate cancer. Clin Cancer Res 6 6 (2000) 2309-2317
89. Nesterova M.V., Johnson M., Cheadle C., et al. Autoantibody cancer biomarker: extracellular protein kinase A. Cancer Res 66 18 (2006) 8971-8974
90. Jones P.A., and Laird P.W. Cancer epigenetics comes of age. Nat Genet 21 2 (1999) 163-167
91. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S.B., and Herman J.G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59 1 (1999) 67-70
92. Fiegl H., Millinger S., Mueller-Holzner E., et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65 4 (2005) 1141-1145
93. Pantel K., Cote R.J., and Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91 13 (1999) 1113-1124
94. Lee T.H., Montalvo L., Chrebtow V., and Busch M.P. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41 2 (2001) 276-282
95. O'Day S.J., Gammon G., Boasberg P.D., et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 17 9 (1999) 2752-2761
96. Hoon D.S., Spugnardi M., Kuo C., Huang S.K., Morton D.L., and Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23 22 (2004) 4014-4022
97. Herrera L.J., Raja S., Gooding W.E., et al. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem 51 1 (2005) 113-118
98. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 18 (1996) 9821-9826
99. Herman J.G. Circulating methylated DNA. Ann NY Acad Sci 1022 (2004) 33-39
100. Lofton-Day C., Model F., Vos T.D., et al. DNA-methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 54 2 (2008) 414-423
101. Hoque M.O., Topaloglu O., et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23 27 (2005) 6569-6575
102. Dulaimi E., Uzzo R.G., Greenberg R.E., Al-Saleem T., and Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 10 6 (2004) 1887-1893
103. Belinsky S.A., Nikula K.J., Palmisano W.A., et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95 20 (1998) 11891-11896
104. Topaloglu O., Hoque M.O., Tokumaru Y., et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 10 7 (2004) 2284-2288
105. Wong I.H., Lo Y.M., Zhang J., et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 59 1 (1999) 71-73
106. Sanchez-Cespedes M., Esteller M., Wu L., et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60 4 (2000) 892-895
107. Silva J.M., Dominguez G., Garcia J.M., et al. Presence of tumor DNA in plasma of breast cancer patients: Clinicopathological correlations. Cancer Res 59 13 (1999) 3251-3256
108. Ruvkun G. Glimpses of a Tiny RNA World. Science 294 5543 (2001) 797-799
109. Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent deletions and down-regulation of micro-RNA genes miR-15 and miR-16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99 24 (2002) 15524-15529
110. Volinia S., Calin G.A., Liu C.G., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103 7 (2006) 2257-2261
111. Ambros V., and Horvitz H.R. Heterochronic mutants of the nematode Caenorhabditis elegans. Science 226 4673 (1984) 409-416
112. Ciafre S.A., Galardi S., Mangiola A., et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334 4 (2005) 1351-1358
113. Iorio M.V., Ferracin M., Liu C.G., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65 16 (2005) 7065-7070
114. Murakami Y., Yasuda T., and Saigo K. Comprehensive analysis of microRNA expression patterns in hepatocelullar carcinoma and non-tumorous tissues. Oncogene 25 17 (2006) 2537-2545
115. Tavazoie S.F., Claudio A., and Thordur O. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451 7175 (2008) 147-152
116. Li M., Feldstein J.T., and Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449 7163 (2007) 682-688
117. Garzon R., Fabbri M., Cimmino A., George A.C., and Carlo M.C. MicroRNA expression and function in cancer. Trends in Mol Med 12 12 (2006) 580-587
118. Rosenfeld N., Aharonov R., Meiri E., et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 28 4 (2008) 462-469
119. Landgraf P., Rusus M., Sheridan A., et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129 7 (2007) 1401-1414
120. Calin G.A., and Croce C.M. MicroRNA-cancer connection: 'the beginning of a new tale'. Cancer Res 66 15 (2006) 7390-7394
121. Jun L., Gad G., Eric A.M., et al. MicroRNA expression profiles classify humanCancers. Nature 435 7043 (2005) 834-838
122. Rai A.J., and Chan D.W. Clinical proteomics: new developments in clinical chemistry. Laboratoriums Medizin 25 (2001) 399-403
123. Palmer-Toy D.E., Kuzdzal S., and Chan D.W. Proteomic approaches to tumor marker discovery. In: Diamandis E.P., Fritsche H.A., Lilja H., Chan D.W., and Schwartz M.K. (Eds). Tumor markers: physiology pathobiology technology and clinical applications (2002), AACC Press, Washington, DC 391-400
124. Huber L.A. Is proteomics heading in the wrong direction?. Nat Rev Mol Cell Biol 4 1 (2003) 74-80
125. Jain K.K. Recent advances in clinical oncoproteomics. J BUON 12 1 (2007) S31-S38
126. Zhou G., Li H., DeCamp D., Chen S., Shu H., and Gong Y. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 1 2 (2002) 117-124
127. Nishizuka S., Charboneau L., Young L., et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci USA 100 24 (2003) 14229-14234
128. Wulfkuhle J.D., Liotta L.A., and Petricoin E.F. Proteomic applications for the early detection of cancer. Nature Rev Cancer 3 4 (2003) 267-275
129. Reymond M.A., and Schlegel W. Proteomics in cancer. Adv Clin Chem 44 (2007) 103-142
130. Cho W.C. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 6 (2007) 25
131. Madoz-Gurpide J., Kuick R., Wang H., Misek D.E., and Hanash S.M. Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol Cell Proteomics 7 2 (2008) 268-281
132. Zhu H., and Snyder M. Protein Chip technology. Curr Opin Chem Biol 7 1 (2003) 55-63
133. Kingsmore S.F. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat Rev Drug Discov 5 4 (2006) 310-320
134. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5 3 (2005) 161-171
135. Srinivas P.R., Barker P., and Srivastava S. Nanotechnology in early detection of cancer. Lab Invest 82 5 (2002) 657-662
136. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351 8 (2004) 781-791
137. Nie S., Xing Y., Kim G.J., and Simons J.W. Nanotechnology applications in cancer. Annu Rev Biomed Eng 9 (2007) 257-288
138. Jain K.K. Applications of Nanobiotechnology in Clinical Diagnostics. Clin Chem 53 11 (2007) 2002-2009
139. Gao X., Cui Y., Levenson R.M., Chung L.W., and Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2 8 (2004) 969-976
140. Voura E.B., Jaiswal J.K., Mattoussi H., and Simon S.M. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med 10 9 (2004) 993-998
141. Wong S.S., Joselevich E., Woolley A.T., Cheung C.L., and Lieber C.M. Covalently functionalized nanotubes as nanometre-sized probes in chemistry and biology. Nature 394 6688 (1998) 52-55
142. Zheng G.F., Patolsky F., Cui Y., Wang W.U., and Lieber C.M. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnol 23 10 (2005) 1294-1301
143. Cuenca A.G., Jiang H., Hochwald S.N., Delano M., Cance W.G., and Grobmyer S.R. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 107 3 (2006) 459-465
144. Maeda M., Kuroda C.S., and Shimura T. Magnetic carriers of iron nanoparticles coated with a functional polymer for high throughput bioscreening. J Appl Phys 99 (2006) 08H103
145. Jain K.K. Role of nanobiotechnology in developing personalized medicine for cancer. Technol Cancer Res Treat 4 (2005) 407-416
146. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70